Skip to content
Peptigraph home

Retatrutide for Gut Health: What the Evidence Shows

What human and animal studies show about Retatrutide for gut health, how strong that evidence is, and what is still unproven.

Medical review pendingGLP-1 / GIP / glucagon triple agonistUpdated
Strongest evidence
None graded
no study with an outcome for gut health (PubMed search, 2 Oct 2026)
Human studies
None found
with an outcome for gut health, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for gut health, in our evidence file (PubMed search, 2 Oct 2026)

Evidence for gut health

None of the study abstracts we summarised for Retatrutide reported an outcome for gut health (PubMed search, 2 Oct 2026). Claims that it helps with gut health are unproven.

How strong is it?

Strongest evidence:No graded study for gut health (PubMed search, 2 Oct 2026)

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

What gut health means in the retatrutide context

MedlinePlus describes digestion as the breakdown of food into a form the body can use, handled by a tube of hollow organs plus the liver, gallbladder and pancreas.[9]

How many retatrutide papers mention gut health

A PubMed title-and-abstract search pairing retatrutide terms with gut health terms returned 80 records on 2026-10-29. That is a keyword-match tally for retatrutide and gut health, not a count of positive findings.

Calculated from pubmed query (retatrutide[tiab] OR LY3437943[tiab]) AND (gut[tiab] OR gastric[tiab] OR gastrointestinal[tiab] OR intestin*[tiab] OR bowel[tiab] OR colitis[tiab] OR Crohn*[tiab]); date 2026-10-29; count 80. Formula: record count of the PubMed [tiab] query on the date shown, as logged by the literature ledger; no arithmetic

What the retrieved retatrutide abstracts say about gut health

In the randomised placebo-controlled obesity trial, the most common adverse events on retatrutide were gastrointestinal, dose-related and mostly mild to moderate, and were partly reduced when the trial started at 2 mg rather than 4 mg.[1]

A review of retatrutide's clinical programme likewise reports that common adverse effects are primarily gastrointestinal and dose-related.[10]

According to the same review, animal studies showed retatrutide delaying gastric emptying and reducing food intake; these are animal findings summarised secondhand.[10]

Other peptides people research for gut health

All peptides for gut health, compared

Common questions

Does Retatrutide help with gut health?

None of the studies we summarised for Retatrutide (PubMed search, 2 Oct 2026) measured an outcome for gut health. Treat claims that it helps with gut health as unproven.

Is Retatrutide approved for gut health?

No. Retatrutide is not FDA approved for any use, including gut health.

What is the best peptide for gut health?

There is no single answer. Our gut health overview compares each candidate by evidence grade and legal status rather than by popularity.

Is there research on retatrutide and gut problems?

PubMed held 80 records matching the retatrutide and gut health search terms when checked on 2026-10-29; a match is not evidence that retatrutide helps with gut health.

Calculated from pubmed query (retatrutide[tiab] OR LY3437943[tiab]) AND (gut[tiab] OR gastric[tiab] OR gastrointestinal[tiab] OR intestin*[tiab] OR bowel[tiab] OR colitis[tiab] OR Crohn*[tiab]); date 2026-10-29; count 80. Formula: record count of the PubMed [tiab] query on the date shown, as logged by the literature ledger; no arithmetic

More on Retatrutide

Sources

  1. 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff AM et al.)New England Journal of Medicine · 2023PMID 37366315Accessed 2 Oct 2026
  2. 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.)New England Journal of Medicine · 2026PMID 42814954Accessed 2 Oct 2026
  3. 3A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (NCT04881760; arms and posted results)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  4. 4PubMed search: retatrutide[tiab] OR LY3437943[tiab] (197 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (96 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (obesity[tiab] OR diabetes[tiab] OR liver[tiab] OR osteoarthritis[tiab]) AND "Clinical Trial"[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  10. 10Retatrutide-A Game Changer in Obesity Pharmacotherapy.Biomolecules · 2025PMID 40563436Accessed 2 Oct 2026

Found an error? Report a correction.